Lil­ly crush­es ex­pec­ta­tions with GLP-1 fran­chise, as sup­ply con­straints ease

Hopes were high com­ing in­to Eli Lil­ly’s sec­ond-quar­ter earn­ings re­sults. But they should have been even high­er.

On Thurs­day, the In­di­anapo­lis drug­mak­er an­nounced that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER